Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761927 | 0.89 | GABRA1 (0.47) | HPGDHTTKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL1761928 | 0.85 | GABRA1 (0.49) | HPGDHTTKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL2338830 | 0.80 | FGFR1 (0.52) | HPGDHTTKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL1761985 | 0.79 | FGFR1 (0.63) | HPGDHTTFGFR1GABRA1GABRG2 | |
| SCHEMBL1762112 | 0.79 | GABRA1 (0.53) | HPGDHTTSMN1; SMN2FGFR1GABRA1 | |
| SCHEMBL1761841 | 0.79 | GABRA1 (0.53) | FGFR1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1762212 | 0.78 | GABRA1 (0.44) | HPGDHTTKMT2ASMN1; SMN2FGFR1 | |
| SCHEMBL1762214 | 0.78 | GABRA1 (0.44) | HPGDHTTKMT2ASMN1; SMN2FGFR1 | |
| SCHEMBL1761890 | 0.77 | FGFR1 (0.45) | HPGDMAPK1SMN1; SMN2FGFR1TP53 | |
| SCHEMBL1762285 | 0.77 | HPGD (0.48) | HPGDKMT2AMAPK1SMN1; SMN2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | HPGD 1966/4885HTT 2103/4885KMT2A 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.